Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

NCT04013854 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage III
Melanoma

Interventions

DRUG: nivolumab
DRUG: Ipilimumab

Sponsor

Abramson Cancer Center at Penn Medicine